#Non-alcoholic Steatohepatitis Clinical Trials Market 2030 | Explore Tumblr Posts and Blogs

adwaitcoherent · 4 years

Text

By 2026, Liver Fibrosis Treatment Market To Surpass US$ 28 Billion - Coherent Market Insights

Liver Fibrosis Treatment Market To exhibit a CAGR of 10.8% over the forecast period (2018 - 2026).

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2320

Description:

Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slowdowns further scarring of liver and results in improvement of condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolve of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Furthermore, research funding by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver disease is expected to spur growth of liver fibrosis treatment market. For instance, in August 2018; professor from College of Science at Virginia Tech and Department of Pharmacology at the University of Virginia received US$ 400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC) with US$ 800,000 matching funds from Continuum Biosciences, Inc. This grant along with matching funds will help researchers to develop drugs to treat nonalcoholic steatohepatitis (NASH).

The global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026) reaching a value of US$ 28.1 billion in 2026.

Global Liver Fibrosis Treatment Market Value (US$ Mn), by Region, 2026

Liver Fibrosis Treatment | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Growing Research and Developments (R&D) Activities and New Developments for Liver Fibrosis Treatment are expected to Augment Market Growth

Liver fibrosis results from various chronic injuries and it often progresses to liver cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Moreover, liver transplantation is only treatment available for advanced stage liver fibrosis. Therefore, new treatment strategies are currently in clinical development stages to treat the liver fibrosis. These treatment option include inhibition of hepatic injury, inhibition of activation of Hematopoietic Stem Cells (HSCs), and inhibition of proliferation of HSCs, inhibition of deposition of type I collagen and proliferation of HSCs. Treatment options for liver fibrosis are usually depends on the underlying cause of the fibrosis. A healthcare professional can treat the underlying liver fibrosis illness conditions, to reduce the effects of liver disease.

Furthermore, key players in the liver fibrosis treatment market are engaged in pre-clinical and clinical studies to develop novel treatment therapies in liver fibrosis regime. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for PTG-300: a subcutaneous injectable developed by Protagonist Therapeutics, Inc. The PTG-300 is currently in clinical development stage for the potential treatment of beta-thalassemia, and can also be used in the liver fibrosis treatment.

For instance, Gilead Sciences, Inc., in October 2017, released the Phase II result studies for Selonsertib: GS-0976 in Nonalcoholic Steatohepatitis (NASH) stage F3 liver fibrosis. These studies reported that, GS-0976 led to significant reductions in concentration of liver fat and fibrosis. Moreover, Gilead Sciences also contain 18 other pipeline molecules in the liver fibrosis treatment, which is further expected to boost company’s revenue in near future.

In April 2017, Tobira Therapeutics, Inc. initiated the clinical study to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult patients with NASH. The study is expected to complete in July 2019.

In April 2017, Bristol-Myers Squibb Company presented the Phase II clinical trial study of BMS-986036: a human fibroblast growth factor. The study results reported that BMS-986036 shows consistent improvement in liver fat, liver injury, and liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH). Increasing number of clinical trials are currently in process for the treatment of liver fibrosis, which are expected to augment the market growth over the forecast period.

Global Liver Fibrosis Treatment Market Share (%), By Treatment Type: 2018 & 2026

Liver Fibrosis Treatment | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

North America market accounted for the largest market share, followed by Europe in 2018. This is owing to increasing burden of potential risk factors leading to liver fibrosis such as obesity, type 2 diabetic, metabolic fibrosis, alcoholic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), among others. For instance, according to the NASH Education Program, 2018 data findings, NAFLD is most common chronic liver condition in Western population of economies in the Europe and the U.S. region as compared to obesity and type 2 diabetes epidemics. Furthermore, the prevalence of NASH is expected to increase by 63% between 2015 and 2030, leading to NASH become a major cause of liver transplantation in the U.S. by 2020.

Furthermore, according to the World Health Organization (WHO), in 2016; more than 1.9 billion adults, 18 years and older were overweight, among which around 650 million were obese. According to Organisation for Economic Co-operation and Development (OECD): Obesity Update 2017 report, obesity levels are expected to be particularly high in the U.S., Mexico and U.K., where 47%, 39% and 35% of the population respectively are projected to be obese in 2030.

Some of the key players operating in the liver fibrosis treatment market include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2320

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Market Analysis #Market Research #Coherent Market Insights

0 notes

rohinic123-blog · 4 years

Text

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size will Observe Substantial Growth by 2027

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Introduction

According to the report, the global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a high CAGR during the forecast period. Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body. Biomarker tools available for diagnosing NASH condition are known as non-invasive tools and few of them are serum biomarkers, biomarker panels, fibrosis biomarkers, Imaging Biomarkers, and others. The others category includes gene biomarkers and oxidative stress biomarkers. Rise in research & development is likely to offer promising biomarkers for the accurate diagnosis of NASH condition.

Planning To Lay Down Future Strategy? Request Brochure Of Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18650

The global non-alcoholic steatohepatitis (NASH) biomarkers market is driven by the increase in prevalence of NAFLD & NASH disease; large unmet needs in terms of disease epidemiology and available diagnostic and therapeutic tools; rise in demand for non-invasive diagnostic methods; increase in geriatric population; growing incidences of obesity and type 2 diabetes; awareness about diagnostic tools; and shift of government focus toward providing better healthcare facilities. These factors are likely to propel the non-alcoholic steatohepatitis (NASH) biomarkers market across the globe.

North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018 and the trend is anticipated to continue during the forecast period. The region’s dominance can be ascribed to the availability of innovative non-invasive biomarkers, presence of key players, growing NASH patient population, technological advancements, awareness about the diagnosis procedure, increase in obesity and type 2 diabetes, and surge in awareness about various causes leading to fatty liver. However, limited accuracy of NASH diagnostic tools such as biomarkers in proper diagnosis are likely to restrain the global non-alcoholic steatohepatitis (NASH) biomarkers market during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Non-alcoholic Steatohepatitis (NASH) Biomarkers Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=18650

Rise in Prevalence of NAFLD and NASH to Propel Global Market

The incidence rate of non-alcoholic liver diseases has increased significantly. Patients with obesity and type 2 diabetes are estimated to be more prone to NAFLD and other liver diseases. This is expected to augment the prevalence of non-alcoholic liver diseases. Changes in lifestyle and high pollution levels are anticipated to boost the prevalence of nonalcoholic liver diseases. This, in turn, is estimated to drive the NASH biomarkers market in the near future.

As per research, worldwide prevalence of NAFLD was estimated to be 25.2%, and NASH was estimated to be in a range of 1.5% to 6.45% respectively in 2019. NASH prevalence across the globe is expected to grow by 63% by 2030.

Increase in Prevalence of Obesity & Type 2 Diabetes to Drive Global Market

Obesity and Type 2 diabetes are the two major lifestyle diseases, which are likely to increase the prevalence of NASH and NAFLD condition. As per NCBI, prevalence of obesity has tripled since 1980 and nearly one-third of the world population is categorized as overweight or obese. According to the Centers for Disease Control and Prevention (CDC), in the U.S., prevalence of obesity was estimated to be 42.4% from 2017 to 2018. The prevalence of severe obesity in the adults in the U.S. was estimated around 9.2% in 2017–2018. Growing incidence of obesity across the population is likely to increase the NASH incidence in the population. People suffering from type 2 diabetes are on verge of developing NAFLD and further into NASH condition. As per the International Diabetes Federation, in 2019, approximately, 463 million adults were suffering from diabetes and the patient population is likely to rise by 700 million by 2045. This statistics is likely to boost the risk of developing NASH condition. Around 70% to 80% of the obese are estimated to suffer from NAFLD, while around 55% of patients with type 2 diabetes are prone to NAFLD.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=18650

Rise in Demand for Non-invasive Diagnostics to Drive Global Market

Liver biopsies are the gold standard in diagnosis and monitoring of NASH in the absence of any alternative diagnostic tools. Liver biopsy is a painful procedure for most patients; bleeding occurs in most cases. The mortality rate associated with liver biopsy stands at one in 10,000. Furthermore, liver biopsies are not entirely accurate, for the diagnosis of the NASH condition. These drive the need of developing non-invasive diagnostic techniques, which includes novel biomarkers for diagnosis and routine monitoring of NASH. Various key players in the pharmaceutical and biotechnology industries are investing in this field. The NASH therapeutics market is projected to reach US$ 35 Bn to US$ 40 Bn by 2024. Companies such as Allergan, Novo Nordisk, and Genfit, and Intercept are investing significantly in the NASH therapeutics market. This is likely to benefit companies offering innovative and emerging noninvasive diagnostic tools such as imaging biomarkers, and gene biomarkers.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Prominent Regions

In terms of region, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, followed by Europe. North America accounted for major share of the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018. This can be attributed to the large patient pool suffering from NASH and NAFLD indication, along with increasing liver diseases. Rise in prevalence of obesity and Type 2 diabetes, rise in demand of non-invasive diagnostic tool such as biomarkers, and adoption of emerging and innovative biomarkers are few major attributable factors for the NASH biomarkers market.

Technological advancements leading to the development of innovative emerging biomarkers is another major factor expected to augment the market in North America. The non-alcoholic steatohepatitis (NASH) biomarkers market in Latin America is likely to expand at a highest CAGR from 2019 to 2027. This can be attributed to rise in prevalence of NASH indication in the population in Latin America, rising liver disease, awareness about diagnosis of NASH indication, increase in healthcare expenditure, and large patient population suffering from type 2 diabetes and obesity and other metabolic syndrome.

Mergers by Key Players to Drive Global Market

The global non-alcoholic steatohepatitis (NASH) biomarkers market is consolidated in terms of number of players. The market is dominated by key players with strong geographic presence and strong product offerings. Leading players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc., and Gilead Sciences, Inc. Merger & acquisition is a major strategy adopted by key players offering NASH biomarkers for non-alcoholic steatohepatitis condition for faster and continuous diagnosis of the condition. For instance, in November 2019, Galectin Therapeutics entered into agreement with Siemens Healthineers, which would enable Siemens Healthineers to utilize Galectin’s Phase 2 NASH-CX clinical trial for supporting the regulatory filing of its ADVIA Centaur Enhanced Liver Fibrosis (ELF) test. This would also allow Siemens Healthineers to use ADVIA Centaur ELF test data from Galectin Therapeutics Phase 3 NASH belapectin clinical trial in the treatment of NASH liver cirrhosis.

More Trending Reports by Transparency Market Research –

Spinal Trauma Devices Market -

https://www.prnewswire.com/news-releases/spinal-trauma-devices-market-to-touch-us4-7-billion-by-2023--says-tmr-300819355.html

Erectile Dysfunction Treatment Devices Market –

https://www.biospace.com/article/-erectile-dysfunction-treatment-devices-market-lessening-stigma-and-more-awareness-likely-to-drive-the-growth-tmr/

0 notes

reportsanddata · 3 years

Text

Non-Alcoholic Steatohepatitis (NASH) Market Revenue Analysis, Company Revenue Share, Global Forecast Till 2027

The global Non-alcoholic Steatohepatitis (NASH) Market is expected to reach USD 13.38 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.

Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.

North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2018, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111

Further key findings from the report suggest

Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT’s lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.

North American market is forecasted to grow at a CAGR of 53% in the coming years. The disease is considered to be one of the leading causes of cirrhosis in adults in the U.S. High incidence of diabetes and obesity in the region are considered to be the main reason behind increasing incidence of NASH. Based on American Liver Foundation's National Medical Advisory Committee currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of the NASH patients suffer from either obesity or diabetes.

Key participants include

Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1111

For the purpose of this report, Reports and Data have segmented global NASH market on the basis of disease cause, drug type, end-user and region:

· Disease Cause Outlook (Revenue, USD Million; 2017-2027)

o Hypertension

o Heart Disease

o High Blood Lipid

o Type 2 Diabetes

o Obesity

· Drug Type Outlook (Revenue, USD Million; 2017-2027)

o Vitamin E & Pioglitazone

o Ocaliva

o Elafibranor

o Selonsertib

o Cenicriviroc

o Others

· End-user Outlook (Revenue, USD Million; 2017-2027)

o Hospitals

o Clinics

o Homecare settings

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1111

· Regional Outlook

o North America

· U.S.

o Europe

· Germany

· UK

o Asia Pacific

· China

· India

· South-east Asia

o Latin America

· Brazil

o MEA

Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.

Browse More Related Reports :

Actigraphy Sensors and Polysomnography Devices Market Analysis

Non-Invasive Brain Trauma Monitoring Devices Market Share

0 notes

reportsanddata · 3 years

Text

Non-Alcoholic Steatohepatitis (NASH) Market Size, Product Launch, Major Companies, Revenue Analysis, Till 2027

Increasing prevalence of obesity coupled with rising adoption of sedentary lifestyle is the major factor influencing market growth.

Market Size – USD 0.41 billion in 2018, Market Growth - CAGR of 52.9%, Market Trends – Growing adoption of NASH therapeutics

The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 13.38 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111

Further key findings from the report suggest

Key participants include Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1111

For the purpose of this report, Reports and Data have segmented global NASH market on the basis of disease cause, drug type, end-user and region:

· Disease Cause Outlook (Revenue, USD Million; 2017-2027)

o Hypertension

o Heart Disease

o High Blood Lipid

o Type 2 Diabetes

o Obesity

· Drug Type Outlook (Revenue, USD Million; 2017-2027)

o Vitamin E & Pioglitazone

o Ocaliva

o Elafibranor

o Selonsertib

o Cenicriviroc

o Others

· End-user Outlook (Revenue, USD Million; 2017-2027)

o Hospitals

o Clinics

o Homecare settings

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1111

· Regional Outlook

o North America

· U.S.

o Europe

· Germany

· UK

o Asia Pacific

· China

· India

· South-east Asia

o Latin America

· Brazil

o MEA

0 notes